Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches.
Treatment of breast cancer brain metastases: radiotherapy and emerging preclinical approaches.
复制标题
DOI：
10.55976/dt.1202216523-36
复制
发表时间：
2022-01-01
期刊：
影响因子：
--
通讯作者：
Chandra, Vyshak
中科院分区：
文献类型：
--
作者：
Mampre, David;Mehkri, Yusuf;Chandra, Vyshak
乳腺是脑转移瘤的常见原发部位之一。乳腺癌BM的放射治疗可能包括全脑放射治疗（WBRT）、立体定向放射外科（SRS）和立体定向放射治疗（SRT），但由于这些干预措施的方案、适应症和结局广泛而多样，因此难以达成共识。总体而言，疾病的传播、患者的功能状态和肿瘤大小都是决定WBRT或SRS治疗的重要因素。到目前为止，先前的研究表明，与SRS相比，WBRT可以改善肿瘤控制，但会增加副作用，但没有随机试验比较这些疗法在乳腺癌BM中的疗效。靶向长链非编码RNA和转录因子（如MALAT 1、HOTAIR、lnc-BM、TGL 1和ATF 3）的疗法有可能预防转移性扩散并以改善的放射敏感性治疗BM。鉴于HER 2+乳腺癌发展为BM的倾向，上述细胞系可能代表未来研究的重要靶点，依维莫司和吡咯替尼的开发同样重要。
The breast is one of the common primary sites of brain metastases (BM). Radiotherapy for BM from breast cancer may include whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), and stereotactic radiotherapy (SRT), but a consensus is difficult to reach because of the wide and varied protocols, indications, and outcomes of these interventions. Overall, dissemination of disease, patient functional status, and tumor size are all important factors in the decision of treatment with WBRT or SRS. Thus far, previous studies indicate that WBRT can improve tumor control compared to SRS, but increase side effects, however no randomized trials have compared the efficacy of these therapies in BM from breast cancer. Therapies targeting long non-coding RNAs and transcription factors, such as MALAT1, HOTAIR, lnc-BM, TGL1, and ATF3, have the potential to both prevent metastatic spread and treat BM with improved radiosensitivity. Given the propensity for HER2+ breast cancer to develop BM, the above-mentioned cell lines may represent an important target for future investigations, and the development of everolimus and pyrotinib are equally important.